Veronica Obregon-Perko,Katherine M. Bricker,Gloria Mensah,Ferzan Uddin,Laura Rotolo,Daryll Vanover,Yesha Desai,Philip J. Santangelo,Sherrie Jean,Jennifer S. Wood,Fawn C. Connor-Stroud,Stephanie Ehnert,Stella J. Berendam,Shan Liang,Thomas H. Vanderford,Katharine J. Bar,George M. Shaw,Guido Silvestri,Amit Kumar,Genevieve G. Fouda,Sallie R. Permar,Ann Chahroudi

Abstract:Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission. We thus investigated viral rebound after analytical treatment interruption (ATI) in 10 infant macaques orally infected with SHIV.C.CH505 and treated with long-term ART. Rebound viremia was detected within 7 to 35 days of ATI in 9 of 10 animals, with posttreatment control of viremia seen in 5 of 5 Mamu-A*01+ macaques. Single-genome sequencing revealed that initial rebound virus was similar to viral DNA present in CD4+ T cells from blood, rectum, and lymph nodes before ATI. We assessed the earliest sites of viral reactivation immediately following ATI using ImmunoPET imaging. The largest increase in signal that preceded detectable viral RNA in plasma was found in the gastrointestinal (GI) tract, a site with relatively high SHIV RNA/DNA ratios in CD4+ T cells before ATI. Thus, the GI tract may be an initial source of rebound virus, but as ATI progresses, viral reactivation in other tissues likely contributes to the composition of plasma virus. Our study provides potentially novel insight into the features of viral rebound in pediatric infection and highlights the application of a noninvasive technique to monitor areas of HIV-1 expression in children.

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART